Neumora Therapeutics

Focus: Neumora Therapeutics is a precision medicine biotech focused on developing novel treatments for brain diseases, particularly neurology and psychiatry indications. The company operates as a pre-revenue stage biotech with a lean pipeline focused on CNS disorders.

Neurology

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Open Jobs

About Neumora Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Neumora Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NMRA-323511

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT06546995Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

Phase 1

Help build intelligence for Neumora Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a precision medicine platform in high-unmet-need CNS space with NMRA-335140 progressing through Phase 3 for Major Depressive Disorder
Join a focused biotech with only 2 active roles, suggesting strategic hiring around core pipeline advancement
Opportunity to shape company direction early-stage with direct impact on drug development for neurology and psychiatry

Watch Out For

Minimal public transparency on funding, employee count, or financial runway creates uncertainty around company stability and growth trajectory
Only 7 active clinical trials across entire pipeline with no marketed products generates significant execution and capitalization risk
Extremely limited hiring (2 open roles) suggests either tight capital constraints or mature team size with low growth opportunities

Generated by Claude from Neumora Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NMRA-335140

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT04221230Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo

Phase 2

NMRA-335140 80 mg

Major Depressive Episode Associated With Bipolar II Disorder

Phase 2

Clinical Trials (1)

NCT06429722To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Phase 2

NMRA-335140

Major Depressive Disorder

Phase 3

Clinical Trials (1)

NCT06058039Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

Phase 3

NMRA-335140

Major Depressive Disorder

Phase 3

Clinical Trials (1)

NCT06029439Study to Assess the Safety and Effectiveness of NMRA-335140-501

Phase 3

NMRA-335140

Major Depressive Disorder

Phase 3

Clinical Trials (1)

NCT06058013Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Phase 3

NMRA-335140

Major Depressive Disorder

Phase 3

Clinical Trials (1)

NCT06029426Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

2 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles